Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
Investing.com - Adaptive Biotechnologies (NASDAQ: ADPT) reported second quarter EPS of $-0.170, $0.07 better than the analyst estimate of $-0.240. Revenue for the quarter came in at $58.88M versus the consensus estimate of $49.4M.
Adaptive Biotechnologies’s stock price closed at $11.06. It is up 22.480% in the last 3 months and up 139.910% in the last 12 months.
Adaptive Biotechnologies saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Adaptive Biotechnologies’s stock price’s past reactions to earnings here.
According to InvestingPro, Adaptive Biotechnologies’s Financial Health score is "fair performance".
Check out Adaptive Biotechnologies’s recent earnings performance, and Adaptive Biotechnologies’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar